Lamivudine and Dolutegravir

Therapeutic indications

Lamivudine and Dolutegravir is indicated for:

Human immunodeficiency virus type 1 infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Dolutegravir and lamivudine combination is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Lamivudine and Dolutegravir is contraindicated in the following cases:

Lactation

Lactation

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Other medicinal product containing dolutegravir, lamivudine or emtricitabine

at least one of
Dolutegravir
Lamivudine
Emtricitabine

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: DOVATO Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈